July 2, 2012
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company Horizon Pharma (Nasdaq: HZNP ) has received a distressing one-star ranking.
With that in mind, let's take a closer look at Horizon's business and see what CAPS investors are saying about the stock right now.
||Deerfield, Ill. (2005)
||Chairman/CEO Timothy Walbert
CFO Robert De Vaere
|Trailing-12-Month Return on Capital
||$80.4 million / $50.4 million
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 30% of the 30 members who have rated Horizon believe the stock will underperform the S&P 500 going forward.
Just this past weekend, one of those bears, All-Star zzlangerhans, touched on the stock's seemingly unsustainable price run:
Last month a sell-side analyst from Cowen estimated 2016 revenues of [$258 million] from Duexis and [$106 million] from Lodotra. That's quite a bold prediction considering Duexis revenues were [$0.9 million] last quarter and Lodotra hasn't even been approved yet. Both Duexis and Lodotra seem to me to be superfluous anti-inflammatory drugs facing heavy competition from established generics.
If you want market-topping returns, you need to protect your portfolio from any undue risk. We've compiled a special free report for investors called "Discover the Next Rule-Breaking Multibagger," which uncovers another small-cap growth play with big potential. The report is 100% free, but it won't be around forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the new TrackPoisedTo CAPS account.